China’s biotech industry saw a dip in deal volume and value for innovative drugs in July after a rebound in the previous month. Chinese biotech companies made a total of 10 deals, with disclosed deal value amounting to over $1.5 billion.
LianBio Acquires Three Potential FIC Therapies for Cancer and IBD.
CANbridge Secures Two In-Licensing Deals for Rare Disease Therapies.
In-Licensing Deals Bring New Acid Reflux and Ophthalmic Treatments in to China
Junshi, Coherus Sign Deal Bringing New Cancer Drug to North America.
China's biopharmaceutical industry completed a dozen licensing deals in the first month of 2021, continuing its 2020 trend of cross-the-border hot licensing deals.